Literature DB >> 11576999

p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator.

R D Abeysinghe1, B T Greene, R Haynes, M C Willingham, J Turner, R P Planalp, M W Brechbiel, F M Torti, S V Torti.   

Abstract

Iron is involved in essential biochemical reactions ranging from respiration to DNA synthesis. Consequently, iron deprivation has been proposed as a strategy for inhibition of tumor cell growth. We recently described a novel iron chelator, tachypyridine [N,N',N"-tris(2-pyridylmethyl)-cis,cis-1,3,5-triaminocyclohexane], and demonstrated that it not only inhibited growth of cultured tumor cells, but was actively cytotoxic. Here we explore the mechanisms underlying tachpyridine cytotoxicity. Using several criteria, including time-lapse video microscopy, DNA staining and TUNEL assays, tachpyridine was shown to specifically induce apoptotic cell death. Further, unlike numerous cytotoxic chemotherapeutic drugs which induce apoptosis by activating p53-dependent pathways, tachpyridine-mediated cell death did not require p53 activation. Although immunoblotting revealed rapid accumulation of p53 following treatment with tachpyridine, p21(WAF1) was not induced. Further, neither cytotoxicity nor apoptosis required p53. p53 null human lung cancer H1299 cells transfected with an ecdysone-inducible p53 exhibited equivalent sensitivity to tachpyridine in the presence and absence of p53, demonstrating the lack of requirement for p53 in an isogenic cell system. Further, time-lapse video microscopy and TUNEL assays demonstrated that both p53 null and p53 wild-type cells underwent apoptotic cell death in response to tachpyridine. In addition, in 55 human cancer cell lines the mean GI(50) of tachpyridine in cells with mutant p53 was virtually identical to the GI(50) in cells with wild-type p53. These results demonstrate that tachpyridine initiates an apoptotic mode of cell death that does not require functional p53. Since over 50% of human tumors contain a functionally defective p53 that reduces sensitivity to commonly used chemotherapeutic agents, such as etoposide and cisplatin, the ability of tachpyridine to induce apoptosis independently of p53 may offer an advantage in anti-tumor therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11576999     DOI: 10.1093/carcin/22.10.1607

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  24 in total

1.  N-picolyl derivatives of Kemp's triamine as potential antitumor agents: a preliminary investigation.

Authors:  Celeste Aida S Regino; Suzy V Torti; Rong Ma; Glenn P A Yap; Kevin A Kreisel; Frank M Torti; Roy P Planalp; Martin W Brechbiel
Journal:  J Med Chem       Date:  2005-12-15       Impact factor: 7.446

Review 2.  Iron and Cancer.

Authors:  Suzy V Torti; David H Manz; Bibbin T Paul; Nicole Blanchette-Farra; Frank M Torti
Journal:  Annu Rev Nutr       Date:  2018-08-21       Impact factor: 11.848

3.  Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation.

Authors:  Jolyn Turner; Constantinos Koumenis; Timothy E Kute; Roy P Planalp; Martin W Brechbiel; Dillon Beardsley; Brooke Cody; Kevin D Brown; Frank M Torti; Suzy V Torti
Journal:  Blood       Date:  2005-07-12       Impact factor: 22.113

4.  A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics.

Authors:  Megan Whitnall; Jonathan Howard; Prem Ponka; Des R Richardson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-26       Impact factor: 11.205

5.  IRP2 regulates breast tumor growth.

Authors:  Wei Wang; Zhiyong Deng; Heather Hatcher; Lance D Miller; Xiumin Di; Lia Tesfay; Guangchao Sui; Ralph B D'Agostino; Frank M Torti; Suzy V Torti
Journal:  Cancer Res       Date:  2013-11-27       Impact factor: 12.701

Review 6.  Iron and cancer: more ore to be mined.

Authors:  Suzy V Torti; Frank M Torti
Journal:  Nat Rev Cancer       Date:  2013-04-18       Impact factor: 60.716

Review 7.  Cellular iron metabolism in prognosis and therapy of breast cancer.

Authors:  Suzy V Torti; Frank M Torti
Journal:  Crit Rev Oncog       Date:  2013

Review 8.  Iron and Cancer: 2020 Vision.

Authors:  Suzy V Torti; Frank M Torti
Journal:  Cancer Res       Date:  2020-09-14       Impact factor: 12.701

9.  NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts.

Authors:  Karuppaiyah Selvendiran; Anna Bratasz; Liyue Tong; Louis J Ignarro; Periannan Kuppusamy
Journal:  Cell Cycle       Date:  2007-09-28       Impact factor: 4.534

10.  Iron deprivation induces apoptosis independently of p53 in human and murine tumour cells.

Authors:  J Truksa; J Kovár; T Valenta; M Ehrlichová; J Polák; P W Naumann
Journal:  Cell Prolif       Date:  2003-08       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.